Evidence map›Paper›PMID 42288884›Full record

ArticleJournal of neuroinflammation2026

Neuroglial P2Y

Charlotte Schubert, Ricardo Lopes Fonseca, Alexandros Hadjilaou, Vanessa Vieira, Karoline Degenhardt, Anna Lena Seemann, Alice Hakimy, Jana K Sonner, Peter Ludewig, Tim Magnus and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Charlotte Schubert *Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0002-2967-4290
Ricardo Lopes Fonseca *Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0009-0006-2655-1638
Alexandros HadjilaouInstitute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0002-2443-9611
Vanessa VieiraInstitute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0002-0205-9669
Karoline DegenhardtDepartment of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0002-1382-5912
Anna Lena SeemannInstitute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0009-0002-1494-7732
Alice HakimyInstitute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jana K SonnerInstitute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0002-4700-272X
Peter LudewigDepartment of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0001-9025-6402
Tim MagnusDepartment of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0001-6232-9555
Marion SchneiderPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0003-2409-3224
Christa E MüllerPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0002-0013-6624
Daniela HirnetDepartment of Animal Physiology, University of Hamburg, Hamburg, Germany.ORCID http://orcid.org/0009-0004-0566-4604
Manuel A FrieseInstitute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. manuel.friese@zmnh.uni-hamburg.de.ORCID http://orcid.org/0000-0001-6380-2420

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular adenosine triphosphate (ATP) and diphosphate (ADP) act as key signalling molecules in the central nervous system (CNS) and regulate neuroinflammatory responses through purinergic receptors. Although astrocytes and neurons undergo profound changes in signalling and metabolism during inflammation, the contribution of specific purinergic pathways to inflammation-induced neurodegeneration remains unclear. Here we show that the ADP/ATP-activated Gq-coupled receptor P2Y

Indexed as

AstrocytesEncephalomyelitis, Autoimmune, ExperimentalNeurogliaNeuroinflammatory DiseasesReceptors, Purinergic P2Y1Signal TransductionAnimalsCells, CulturedFemaleMiceMice, Inbred C57BLMice, KnockoutNeuronsReceptors, Purinergic P2Y1Adenine nucleotidesEAENeuroinflammationNeuron-glial crosstalkPurine receptors

Identifiers

PMID42288884
PMCPMC13263940

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.